News

People with scleroderma may have slightly elevated symptoms of anxiety compared to the general population, particularly those in specific sociodemographic subgroups, an international study reported. Researchers found that several demographic features, such as being younger or non-white, as well as disease features, including gastrointestinal symptoms, were associated with higher…

Increasing levels of self-reactive antibodies in the bloodstream after the start of treatment are associated with the progression of systemic sclerosis (SSc), according to recent research. “We hypothesize that rising antibody [levels] during treatment may reflect ongoing immune activation, insufficient therapeutic response, or impending flare, whereas decreasing [levels] may…

The presence and severity of interstitial lung disease in people with systemic sclerosis (SSc) are associated with a specific combination of bacteria in the gut, a study suggests. “These species or their metabolic products may influence ILD [disease processes] and represent novel treatment targets,” the study’s researchers wrote. The…

Sexual dysfunction is common among people with systemic scleroderma, but is rarely discussed between patients and their doctors, a new study shows. In the study, “Sexual dysfunction and perceptions of rheumatologist engagement on this issue in patients with systemic sclerosis,” the researchers said the reasons for…

Infection with Epstein-Barr virus (EBV), the virus that causes mononucleosis, may increase the risk of developing systemic sclerosis (SSc), according to a new analysis of genetic data. Findings also indicate that SSc is less likely to develop in people who’ve been infected with human immunodeficiency virus (HIV) or SARS-CoV-2, the…

Modifying mesenchymal stem cells (MSCs) — a type of stem cell found in various tissues and, in this case, taken from the umbilical cord of mice — and using clumps of them in a mouse model of systemic sclerosis (SSc) was found to ease signs of skin and lung…

Efzofitimod was found to be generally safe and well tolerated by patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in a proof-of-concept Phase 2 study. No treatment-related serious side effects were reported, with efzofitimod showing early signs of efficacy. In addition, the last patient visit has been completed in…

The immune signaling protein interleukin-40, or IL-40, may be involved in developing systemic sclerosis (SSc), a study from the Czech Republic suggests. Elevated levels of IL-40 were found in the bloodstream of adults with SSc and correlated with worse disease activity, digestive problems, and markers of inflammation and fibrosis.

The first patient with systemic sclerosis (SSc) has been dosed in a Phase 1 trial of Adicet Bio’s investigational CAR T-cell therapy for autoimmune conditions, called ADI-001, the company has announced. Recruitment in the open-label trial (NCT06375993) is ongoing at one site in California. It’s expected…

The National Scleroderma Foundation has recognized several individuals — leaders in advocacy, fundraising, and patient support — and regional chapters for their service in advancing scleroderma awareness and research. The 12 awards, given at the 2025 National Scleroderma Conference, held July 18-20 in St. Louis, were given for…